Tyra Biosciences (NASDAQ:TYRA – Get Free Report) and TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.
Valuation & Earnings
This table compares Tyra Biosciences and TransCode Therapeutics’ revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tyra Biosciences | N/A | N/A | -$69.13 million | ($1.61) | -11.14 |
| TransCode Therapeutics | N/A | N/A | -$18.55 million | ($774.80) | 0.00 |
Tyra Biosciences is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tyra Biosciences | 0 | 1 | 2 | 0 | 2.67 |
| TransCode Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Tyra Biosciences presently has a consensus price target of $22.00, suggesting a potential upside of 22.63%. TransCode Therapeutics has a consensus price target of $480.00, suggesting a potential upside of 41,279.31%. Given TransCode Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe TransCode Therapeutics is more favorable than Tyra Biosciences.
Profitability
This table compares Tyra Biosciences and TransCode Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tyra Biosciences | N/A | -30.26% | -28.53% |
| TransCode Therapeutics | N/A | -934.78% | -276.08% |
Institutional and Insider Ownership
84.1% of Tyra Biosciences shares are owned by institutional investors. 15.4% of Tyra Biosciences shares are owned by company insiders. Comparatively, 1.5% of TransCode Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Tyra Biosciences has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of -0.36, indicating that its share price is 136% less volatile than the S&P 500.
Summary
Tyra Biosciences beats TransCode Therapeutics on 7 of the 11 factors compared between the two stocks.
About Tyra Biosciences
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
About TransCode Therapeutics
TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
